Case scenario 

Ping, 45, is a regular patient of the pharmacy and presents a repeat script for nortriptyline. He has had a partial response to this medicine, reporting improvements in chronic pain. When you inquire about any potential new medicines, he mentions he recently visited a new GP who prescribed a trial of a THC-dominant medicinal cannabis flower dried for vaporization, which he is yet to have dispensed. The new GP was not aware of his nortriptyline use.

Learning objectives

After completing this activity pharmacists should be able to:

  • Describe the most common indications medicinal cannabis-based products (CBPs) are prescribed for in Australia
  • Explain the common mechanisms whereby cannabis and CBPs may interact with other medicines
  • Discuss examples of clinically observed drug interactions between CBPs and commonly co-prescribed medicines
  • Discuss the role of the pharmacist in reviewing for and identifying actual or potential drug interactions with CBPs.

Competency (2016) standards addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.2, 3.3, 3.5

Already read the CPD i

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.

CPD LOGIN
Click here to become a member

RELATED ARTICLESMORE FROM AUTHOR